HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RARE
Ultragenyx Pharmaceutical Inc.
There isn't enough reported data to score RARE yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RARE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
RARE's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RARE PE Valuation
RARE has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 9.8x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RARE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
RARE has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RARE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.67 | — |
| Q3 2026 | -$5.18 | +$0.71 |
| Q2 2026 | -$5.83 | -$0.35 |
| Q1 2026 | -$6.10 | -$0.27 |
| Q4 2025 | -$5.83 | +$0.46 |
| Q3 2025 | -$5.89 | +$0.50 |
| Q2 2025 | -$5.48 | +$1.74 |
| Q1 2025 | -$5.83 | +$2.12 |
| Q4 2024 | -$6.29 | +$1.96 |
RARE has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RARE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over RARE on profitability, with a higher operating margin.
RARE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $173M | +8.2% |
| Q2 2026 | $214M | +29% |
| Q1 2026 | $136M | -2.4% |
| Q4 2025 | $207.3M | +26% |
| Q3 2025 | $159.9M | +15% |
| Q2 2025 | $166.5M | +13% |
| Q1 2025 | $139.3M | +28% |
| Q4 2024 | $164.9M | +29% |
RARE's revenue is growing: $173M last quarter, up 8.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -64% | +43 points |
| Q2 2026 | -35% | +30 points |
| Q1 2026 | -124% | -22 points |
| Q4 2025 | -55% | +20 points |
| Q3 2025 | -107% | -12 points |
| Q2 2025 | -65% | +14 points |
| Q1 2025 | -103% | +49 points |
| Q4 2024 | -74% | +22 points |
RARE's operating margin was −64% last quarter, up 43 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over RARE on cash generation, producing positive trailing cash flow while its opponent burns cash.
RARE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$45M | +$47.7M |
| Q2 2026 | -$98M | +$12.7M |
| Q1 2026 | -$198M | -$30.2M |
| Q4 2025 | -$100.8M | -$20.6M |
| Q3 2025 | -$92.7M | -$24.1M |
| Q2 2025 | -$110.7M | -$31.8M |
| Q1 2025 | -$167.8M | +$26.1M |
| Q4 2024 | -$80.2M | +$5.3M |
RARE has burned cash in almost every quarter: −$442M over the past year, against −$451M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RARE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RARE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +200K shares |
| 1 year | +2.3% | +2.3M shares |
| 3 years | +42% | +30.4M shares |
| 5 years | +50% | +34.2M shares |
| Available history | +80% | +45.5M shares |
RARE has 102M diluted shares, up 2.3% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RARE Net Leverage
RARE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RARE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.0 | Neutral |
| Stochastic | 20.3 | Neutral |
RARE's weekly RSI is 39 (neutral) and its Stochastic is 20 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RARE PE vs Healthcare Sector
RARE has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RARE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.4 | 5.6% above |
| 20 week MA | $21.0 | 22% below |
| 50 week MA | $23.4 | 31% below |
| 100 week MA | $29.5 | 45% below |
| 200 week MA | $37.2 | 56% below |
RARE has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over RARE on returns for 2026, with the stronger performance.
RARE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $43.4 | $172.9 | +298% |
| 2021 | $172.9 | $84.7 | -51% |
| 2022 | $84.7 | $43.5 | -49% |
| 2023 | $43.5 | $47.8 | +9.9% |
| 2024 | $47.8 | $43.4 | -9.2% |
| 2025 | $43.4 | $34.2 | -21% |
| 2026 YTD | $34.2 | $16.3 | -52% |
RARE's yearly returns have swung widely, from +298% in 2020 to −51% in 2021. It's down 52% so far in 2026.